Package Leaflet: Information for the Patient
Sitagliptin/Metformin Combix 50 mg/850 mg film-coated tablets EFG
Sitagliptin/Metformin Combix 50 mg/1000 mg film-coated tablets EFG
sitagliptin/metformin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sitagliptin/Metformin Combix contains two different medicines called sitagliptin and metformin.
They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps increase the amount of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps lower your blood sugar levels. This medicine can be used alone or with certain other diabetes medicines (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a disease in which your body does not produce enough insulin and the insulin your body produces does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart (cardiac) problems, kidney (renal) problems, blindness, and amputations.
Do not takeSitagliptin/Metformin Combix
Do not take sitagliptin/metformin if any of the above applies to you and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking sitagliptin/metformin.
Warnings and precautions
There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with sitagliptin/metformin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking sitagliptin/metformin.
Risk of lactic acidosis
Sitagliptin/metformin may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting, or alcohol intake, dehydration (see more information below), liver problems, and any medical condition in which a part of your body has a reduced supply of oxygen (such as acute and severe heart problems).
If any of the above applies to you, consult your doctor for further instructions.
Consult your doctor immediately to find out how to proceed if:
Stop taking sitagliptin/metformin for a short period if you have a condition that may be associated with dehydration(significant loss of body fluids), such as severe vomiting, diarrhea, fever, heat exposure, or if you drink less fluid than usual. Consult your doctor for further instructions.
Stop taking sitagliptin/metformin and contact a doctor or the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and must be treated in a hospital.
Consult your doctor or pharmacist before starting to take sitagliptin/metformin:
If you need to undergo major surgery, you should stop taking sitagliptin/metformin during the procedure and for some time after. Your doctor will decide when you should stop taking sitagliptin/metformin and when you can restart it.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking sitagliptin/metformin.
During treatment with sitagliptin/metformin, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Children and adolescents under 18 years should not use this medicine. It is not effective in children and adolescents aged 10 to 17 years. It is not known if this medicine is safe and effective when used in children under 10 years.
Other medicines and Sitagliptin/Metformin Combix
If you need to be given an injection of a contrast agent that contains iodine into your bloodstream, for example, in the context of an X-ray or scan, you should stop taking sitagliptin/metformin before or at the time of the injection. Your doctor will decide when you should stop taking sitagliptin/metformin and when you can restart it.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of sitagliptin/metformin. It is especially important to mention the following:
Taking Sitagliptin/Metformin Combix with alcohol
Avoid excessive alcohol intake while taking sitagliptin/metformin, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not take this medicine during pregnancy. You should not take this medicine if you are breast-feeding. See section 2, Do not takesitagliptin/metformin.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, cases of dizziness and drowsiness have been reported during treatment with sitagliptin, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause hypoglycemia, which may affect your ability to drive or use machines or work without a secure support.
Sitagliptin/Metformin Combix contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet, which is essentially “sodium-free”.
Take this medicine exactly as your doctor has told you.
If you are not sure, ask your doctor or pharmacist.
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful to distribute your carbohydrate intake evenly throughout the day.
It is unlikely that treatment with this medicine alone will cause you to have low blood sugar (hypoglycemia). Low blood sugar can occur when this medicine is taken with a sulfonylurea or insulin, so your doctor may consider it necessary to reduce the dose of your sulfonylurea or insulin.
If you take more Sitagliptin/Metformin Combix than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you take more than the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, nausea or vomiting, stomach pain, unexplained weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
If you forget to take Sitagliptin/Metformin Combix
If you forget to take a dose, take it as soon as you remember. If you do not remember until the time of your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose of this medicine.
If you stop taking Sitagliptin/Metformin Combix
Keep taking this medicine for as long as your doctor tells you to, so it can help control your blood sugar levels. Do not stop taking this medicine without talking to your doctor first. If you stop taking sitagliptin/metformin, your blood sugar levels may increase again.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP taking sitagliptin/metformin and consult your doctor immediately if you notice any of the following serious adverse effects:
Sitagliptin/metformin may cause a very rare (affecting up to 1 in 10,000 people) but very serious adverse effect called lactic acidosis (see section "Warnings and Precautions"). If this happens to you, you must stop taking sitagliptin/metformin and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/peeling of the skin, and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change the medicine for the treatment of diabetes.
Some patients who took metformin have experienced the following adverse effects after starting treatment with sitagliptin:
Frequent (may affect up to 1 in 10 people): low blood sugar levels, nausea, gas, vomiting
Infrequent (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness
Some patients have experienced diarrhea, nausea, gas, constipation, stomach pain, or vomiting when starting treatment with the combination of sitagliptin and metformin (frequency classified as frequent).
Some patients have experienced the following adverse effects when taking this medicine along with a sulfonylurea such as glimepiride:
Very frequent (may affect more than 1 in 10 people): low blood sugar levels
Frequent: constipation
Some patients presented the following adverse effects while taking this medicine in combination with pioglitazone:
Frequent: swelling of hands or feet
Some patients presented the following adverse effects while taking this medicine in combination with insulin:
Very frequent: low blood sugar levels
Infrequent: dry mouth, headache
Some patients have experienced the following adverse effects during clinical studies while taking sitagliptin alone (one of the medicines that contains Sitagliptin/Metformin Combix) or during use after the approval of sitagliptin/metformin or sitagliptin alone or with other diabetes medicines:
Frequent: low blood sugar levels, headache, upper respiratory tract infection, nasal congestion or nasal mucosity, and sore throat, arthrosis, pain in the arm or leg
Infrequent: dizziness, constipation, itching
Rare: reduction in platelet count
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Some patients have experienced the following adverse effects after taking metformin alone:
Very frequent: nausea, vomiting, diarrhea, stomach pain, and loss of appetite. These symptoms may appear when you start taking metformin and usually disappear
Frequent: metallic taste, decrease or low levels of vitamin B12 in blood (symptoms may include extreme fatigue, pain, and redness of the tongue (glossitis), tingling (paresthesia), or pale or yellowish skin). Your doctor may ask you for some tests to determine the cause of your symptoms, as some of them may also be caused by diabetes or other unrelated health problems
Very rare: hepatitis (a liver problem), hives, skin redness (rash), or itching
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the blister or bottle and on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30 °C.
Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines you no longer need in the SIGRE Point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Sitagliptin/Metformin Combix
Core of the tablet: microcrystalline cellulose, povidone (K29/32), sodium lauryl sulfate, magnesium stearate.
Film coating (50 mg/850 mg): polyethylene glycol copolymer grafted with polyvinyl alcohol (E1209), talc (E553b), titanium dioxide (E171), monoglycerides and diglycerides of fatty acids (E471), polyvinyl alcohol (E1203), and red iron oxide (E172)
Film coating (50 mg/1000 mg): polyethylene glycol copolymer grafted with polyvinyl alcohol (E1209), talc (E553b), titanium dioxide (E171), red iron oxide (E172), monoglycerides and diglycerides of fatty acids (E471), polyvinyl alcohol (E1203), and black iron oxide (E172).
Appearance of the Product and Package Contents
Sitagliptin/Metformin Combix 50 mg/850 mg film-coated tablets EFG: film-coated tablet, oval-shaped, biconvex, with approximate dimensions of 20.5 mm x 9.5 mm, pink in color, engraved with "S476" on one side and flat on the other.
Sitagliptin/Metformin Combix 50 mg/1000 mg film-coated tablets EFG: film-coated tablet, oval-shaped, biconvex, with approximate dimensions of 21.5 mm x 10.0 mm, brown in color, engraved with "S477" on one side and flat on the other.
Sitagliptin/Metformin Combix 50 mg/850 mg film-coated tablets EFG are presented in
Packages of 14, 28, 30, 56, 60, 196, and 210 tablets.
Packages of 100 and 196 tablets.
Sitagliptin/Metformin Combix 50 mg/1000 mg film-coated tablets EFG are presented in
Packages of 14, 28, 30, 56, 60, 196, and 210 tablets.
Packages of 100 and 196 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Laboratorios Combix, S.L.U.
C/ Badajoz 2, Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Laboratorios Liconsa S.A.
Avda. Miralcampo, nº 7, Polígono Industrial Miralcampo
19200 Azuqueca de Henares (Guadalajara)
Spain
Date of the Last Revision of this Prospectus: July 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/